HIV and anal cancer outcomes: A single institution's experience

Melissa E. Hogg, Daniel A. Popowich, Ed C. Wang, Kristina D. Kiel, Steven J. Stryker, Amy L Halverson

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


PURPOSE: The purpose of this study is to identify the effect of HIV status on outcome of treatment for squamous-cell carcinoma of the anal canal. METHODS: A retrospective review was performed on all patients with squamous-cell carcinoma of the anal canal treated at a single academic institution between January 1996 and December 2006. RESULTS: Our search identified 87 (21 HIV-positive) patients who had invasive squamous-cell cancer. The median follow-up was 38 months. Eighty-five percent of HIV-negative patients and 81 percent of HIV-positive were identified as complete responders at 6 weeks after completion of combined modality therapy. Eight percent of HIV-negative and 29 percent of HIV-positive patients developed recurrent disease after 6 months (P = 0.0009). Overall survival for HIV-negative and HIV-positive patients was 71 percent and 73 percent, respectively. CONCLUSIONS: HIV-positive patients respond equally to combined modality therapy but have recurrences more frequently than patients who are HIV negative. Overall survival in these two groups is equivalent.

Original languageEnglish (US)
Pages (from-to)891-897
Number of pages7
JournalDiseases of the Colon and Rectum
Issue number5
StatePublished - May 1 2009


  • Anal canal cancer
  • Combined modality therapy
  • HIV
  • Squamous-cell carcinoma

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'HIV and anal cancer outcomes: A single institution's experience'. Together they form a unique fingerprint.

Cite this